Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055757 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Phase 2 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00055757: Completed Phase 2 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
NCT00055757 is a Phase 2 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants, below the 687-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055757, a Phase 2 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of combining tipifarnib with gemcitabine and cisplatin in treating patients who have stage III or stage IV non-small cell lung cancer. Drugs used in chemotherapy such as gemcitabine and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining tipifarnib with combination chemotherapy may kill more tumor cells.
Primary Outcome
Ninety-five percent confidence intervals for the true success proportion will be calculated.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
- DRUG tipifarnib
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2003-10 |
| Phase | Phase 2 |
What the finished NCT00055757 record still lists
NCT00055757 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 687-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00055757 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00055757 about?
NCT00055757 is a clinical study titled "Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". Phase II trial to study the effectiveness of combining tipifarnib with gemcitabine and cisplatin in treating patients who have stage III or stage IV non-small cell lung cancer. Drugs used in chemotherapy such as gemcitabine and cisplatin use different ways to stop tumor cells from dividing so they s...
What is the current status of trial NCT00055757?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2003-10.
What conditions does trial NCT00055757 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT00055757?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), gemcitabine hydrochloride (DRUG), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00055757?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055757 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00055757's enrollment target sits among peer trials
48 14th of 23 higher than 10 of 23 other Stage IV Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
COMPLETED · Phase 2
-
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
COMPLETED · Phase 2
-
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia